In conclusion, the result that CCND2 is down-regulated in renal cell cancer strongly suggests that the function of CCND2 is not only limited to its role in cell cycle transition from G1 to S. The cancer-specific loss of CCND2 in renal carcinoma and suppression of RCC cell growth provide clues for investigating a possible role of CCND2 in carcinogenesis in kidney and the methylation of its promoter may function as an optional biomarker for clinical application. This evidence concerns the gene CCND2 and renal carcinoma.